Urinary Tissue Inhibitor of Metalloproteinases-2 and Insulin-Like Growth Factor–Binding Protein 7 Do Not Correlate With Disease Severity in ADPKD Patients

Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst formation and variable renal function decline that frequently leads to end-stage renal failure. With the advent of renoprotective treatment, there is renewed interest in noninvasive biomarkers to...

Full description

Bibliographic Details
Main Authors: Shosha E.I. Dekker, L. Renee Ruhaak, Fred P.H.T.M. Romijn, Esther Meijer, Christa M. Cobbaert, Johan W. de Fijter, Darius Soonawala, Joost P.H. Drenth, Ron T. Gansevoort, Dorien J.M. Peters, Jack F. Wetzels, Robert Zietse
Format: Article
Language:English
Published: Elsevier 2019-06-01
Series:Kidney International Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024919301160
_version_ 1811278660613701632
author Shosha E.I. Dekker
L. Renee Ruhaak
Fred P.H.T.M. Romijn
Esther Meijer
Christa M. Cobbaert
Johan W. de Fijter
Darius Soonawala
Joost P.H. Drenth
Johan W. de Fijter
Ron T. Gansevoort
Dorien J.M. Peters
Jack F. Wetzels
Robert Zietse
author_facet Shosha E.I. Dekker
L. Renee Ruhaak
Fred P.H.T.M. Romijn
Esther Meijer
Christa M. Cobbaert
Johan W. de Fijter
Darius Soonawala
Joost P.H. Drenth
Johan W. de Fijter
Ron T. Gansevoort
Dorien J.M. Peters
Jack F. Wetzels
Robert Zietse
author_sort Shosha E.I. Dekker
collection DOAJ
description Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst formation and variable renal function decline that frequently leads to end-stage renal failure. With the advent of renoprotective treatment, there is renewed interest in noninvasive biomarkers to help identify patients at risk of rapid disease progression at early stages. Urinary tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor–binding protein 7 (IGFBP7) have been validated as early markers of acute kidney injury. Because these markers are associated with tubular damage, we studied the performance of both markers in a cohort with chronic tubular pathology. We investigated whether these biomarkers may be useful to evaluate disease severity in ADPKD. Methods: In a cross-sectional analysis, we measured TIMP-2 and IGFBP7 in stored spot urine samples of patients with ADPKD with various stages of chronic kidney disease (CKD) and healthy controls by enzyme-linked immunosorbent assay. Renal function was estimated using the CKD–Epidemiology Collaboration equation. Patients were stratified according to the Kidney Disease Outcomes Quality Initiative classification for CKD. In a subset of patients, total kidney volume (TKV; using magnetic resonance imaging [MRI]) was measured. Results: In 296 patients with ADPKD (45.5 ± 11.5 years, 51.0% female, serum creatinine 106 [85–147] μmol/l), urine levels of TIMP-2 and IGFBP7 were not increased or tended to be lower as compared with 71 healthy controls (46.5 ± 18.5 years, 72.6% female). The levels did not differ across CKD stages, which remained so after correcting for urine creatinine or osmolality, and for age, sex, and urine protein in multivariable analyses. Conclusions: Urinary levels of TIMP-2 and IGFBP7 were not higher in patients with ADPKD, and did not correlate with disease severity. Keywords: ADPKD, chronic renal dysfunction, disease severity, insulin-like growth factor–binding protein 7, tissue inhibitor of metalloproteinases-2, urinary biomarkers
first_indexed 2024-04-13T00:39:44Z
format Article
id doaj.art-6c2b04f4dfb84a14b998680513ff709f
institution Directory Open Access Journal
issn 2468-0249
language English
last_indexed 2024-04-13T00:39:44Z
publishDate 2019-06-01
publisher Elsevier
record_format Article
series Kidney International Reports
spelling doaj.art-6c2b04f4dfb84a14b998680513ff709f2022-12-22T03:10:11ZengElsevierKidney International Reports2468-02492019-06-0146833841Urinary Tissue Inhibitor of Metalloproteinases-2 and Insulin-Like Growth Factor–Binding Protein 7 Do Not Correlate With Disease Severity in ADPKD PatientsShosha E.I. Dekker0L. Renee Ruhaak1Fred P.H.T.M. Romijn2Esther Meijer3Christa M. Cobbaert4Johan W. de Fijter5Darius Soonawala6Joost P.H. DrenthJohan W. de FijterRon T. GansevoortDorien J.M. PetersJack F. WetzelsRobert ZietseDepartment of Nephrology, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Nephrology, University Medical Center Groningen, Groningen, the NetherlandsDepartment of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Nephrology, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Nephrology, Leiden University Medical Center, Leiden, the Netherlands; Department of Internal Medicine, Haga Teaching Hospital, The Hague, The Netherlands; Correspondence: Darius Soonawala, Department of Nephrology, Leiden University Medical Center (LUMC), P.O. Box 9600, 2300 RC Leiden, the Netherlands.Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst formation and variable renal function decline that frequently leads to end-stage renal failure. With the advent of renoprotective treatment, there is renewed interest in noninvasive biomarkers to help identify patients at risk of rapid disease progression at early stages. Urinary tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor–binding protein 7 (IGFBP7) have been validated as early markers of acute kidney injury. Because these markers are associated with tubular damage, we studied the performance of both markers in a cohort with chronic tubular pathology. We investigated whether these biomarkers may be useful to evaluate disease severity in ADPKD. Methods: In a cross-sectional analysis, we measured TIMP-2 and IGFBP7 in stored spot urine samples of patients with ADPKD with various stages of chronic kidney disease (CKD) and healthy controls by enzyme-linked immunosorbent assay. Renal function was estimated using the CKD–Epidemiology Collaboration equation. Patients were stratified according to the Kidney Disease Outcomes Quality Initiative classification for CKD. In a subset of patients, total kidney volume (TKV; using magnetic resonance imaging [MRI]) was measured. Results: In 296 patients with ADPKD (45.5 ± 11.5 years, 51.0% female, serum creatinine 106 [85–147] μmol/l), urine levels of TIMP-2 and IGFBP7 were not increased or tended to be lower as compared with 71 healthy controls (46.5 ± 18.5 years, 72.6% female). The levels did not differ across CKD stages, which remained so after correcting for urine creatinine or osmolality, and for age, sex, and urine protein in multivariable analyses. Conclusions: Urinary levels of TIMP-2 and IGFBP7 were not higher in patients with ADPKD, and did not correlate with disease severity. Keywords: ADPKD, chronic renal dysfunction, disease severity, insulin-like growth factor–binding protein 7, tissue inhibitor of metalloproteinases-2, urinary biomarkershttp://www.sciencedirect.com/science/article/pii/S2468024919301160
spellingShingle Shosha E.I. Dekker
L. Renee Ruhaak
Fred P.H.T.M. Romijn
Esther Meijer
Christa M. Cobbaert
Johan W. de Fijter
Darius Soonawala
Joost P.H. Drenth
Johan W. de Fijter
Ron T. Gansevoort
Dorien J.M. Peters
Jack F. Wetzels
Robert Zietse
Urinary Tissue Inhibitor of Metalloproteinases-2 and Insulin-Like Growth Factor–Binding Protein 7 Do Not Correlate With Disease Severity in ADPKD Patients
Kidney International Reports
title Urinary Tissue Inhibitor of Metalloproteinases-2 and Insulin-Like Growth Factor–Binding Protein 7 Do Not Correlate With Disease Severity in ADPKD Patients
title_full Urinary Tissue Inhibitor of Metalloproteinases-2 and Insulin-Like Growth Factor–Binding Protein 7 Do Not Correlate With Disease Severity in ADPKD Patients
title_fullStr Urinary Tissue Inhibitor of Metalloproteinases-2 and Insulin-Like Growth Factor–Binding Protein 7 Do Not Correlate With Disease Severity in ADPKD Patients
title_full_unstemmed Urinary Tissue Inhibitor of Metalloproteinases-2 and Insulin-Like Growth Factor–Binding Protein 7 Do Not Correlate With Disease Severity in ADPKD Patients
title_short Urinary Tissue Inhibitor of Metalloproteinases-2 and Insulin-Like Growth Factor–Binding Protein 7 Do Not Correlate With Disease Severity in ADPKD Patients
title_sort urinary tissue inhibitor of metalloproteinases 2 and insulin like growth factor binding protein 7 do not correlate with disease severity in adpkd patients
url http://www.sciencedirect.com/science/article/pii/S2468024919301160
work_keys_str_mv AT shoshaeidekker urinarytissueinhibitorofmetalloproteinases2andinsulinlikegrowthfactorbindingprotein7donotcorrelatewithdiseaseseverityinadpkdpatients
AT lreneeruhaak urinarytissueinhibitorofmetalloproteinases2andinsulinlikegrowthfactorbindingprotein7donotcorrelatewithdiseaseseverityinadpkdpatients
AT fredphtmromijn urinarytissueinhibitorofmetalloproteinases2andinsulinlikegrowthfactorbindingprotein7donotcorrelatewithdiseaseseverityinadpkdpatients
AT esthermeijer urinarytissueinhibitorofmetalloproteinases2andinsulinlikegrowthfactorbindingprotein7donotcorrelatewithdiseaseseverityinadpkdpatients
AT christamcobbaert urinarytissueinhibitorofmetalloproteinases2andinsulinlikegrowthfactorbindingprotein7donotcorrelatewithdiseaseseverityinadpkdpatients
AT johanwdefijter urinarytissueinhibitorofmetalloproteinases2andinsulinlikegrowthfactorbindingprotein7donotcorrelatewithdiseaseseverityinadpkdpatients
AT dariussoonawala urinarytissueinhibitorofmetalloproteinases2andinsulinlikegrowthfactorbindingprotein7donotcorrelatewithdiseaseseverityinadpkdpatients
AT joostphdrenth urinarytissueinhibitorofmetalloproteinases2andinsulinlikegrowthfactorbindingprotein7donotcorrelatewithdiseaseseverityinadpkdpatients
AT johanwdefijter urinarytissueinhibitorofmetalloproteinases2andinsulinlikegrowthfactorbindingprotein7donotcorrelatewithdiseaseseverityinadpkdpatients
AT rontgansevoort urinarytissueinhibitorofmetalloproteinases2andinsulinlikegrowthfactorbindingprotein7donotcorrelatewithdiseaseseverityinadpkdpatients
AT dorienjmpeters urinarytissueinhibitorofmetalloproteinases2andinsulinlikegrowthfactorbindingprotein7donotcorrelatewithdiseaseseverityinadpkdpatients
AT jackfwetzels urinarytissueinhibitorofmetalloproteinases2andinsulinlikegrowthfactorbindingprotein7donotcorrelatewithdiseaseseverityinadpkdpatients
AT robertzietse urinarytissueinhibitorofmetalloproteinases2andinsulinlikegrowthfactorbindingprotein7donotcorrelatewithdiseaseseverityinadpkdpatients